Welcome to Peptide Prescriber Academy. PPA is the operational layer prescribers consult between visits. Academic CME teaches the science. PPA is the layer on top — per-peptide regulatory status updated monthly, protocol cards, chart-note templates, an Operational Peptide Reference covering 48 peptides, and a peer case-discussion community. HOW PPA IS ORGANIZED Six tracks of curriculum. Track 1 Peptide Foundations. Track 2 GLP Peptides. Track 3 Healing and Immune Peptides. Track 4 GH, Performance, and Longevity. Track 5 Cognitive, Sexual Health, and Specialty. Track 6 Building Your Peptide Practice. Curriculum is non-linear after Module 0. Reference Library. The Operational Peptide Reference (a single bound atlas of 48 prescriber one-sheets), plus the individual one-sheets and a "How to Use the Reference Library" guide. Protocol Card Library. Thirteen condensed point-of-care protocol cards — Tier 1 first-line cards (GLP initiation, healing stacks, GH secretagogue protocols, longevity, immune, cognitive, sexual health) and Tier 2 advanced cards (advanced GLP stacking, injury recovery, metabolic optimization, bioregulator deep protocol). Monthly Regulatory Currency Tracker. First Wednesday of every month. FDA bulks list changes, DEA scheduling, state pharmacy board updates, peer-reviewed research, dates to watch. The April 2026 inaugural edition is live now. Case-discussion community. This feed. Where members pressure-test cases peer-to-peer. WHERE TO START 1. Open Module 0 in the Start Here folder of the classroom. Ten minutes. It frames how to use the rest. 2. 2. Read this month's Regulatory Currency Tracker. Note anything that affects a protocol you currently use. 3. 3. Reply to this post and introduce yourself in the comments. State your license type and one peptide protocol you want to sharpen. COMMUNITY NORMS Peer-to-peer professional. Cite sources when relevant. Disagreement is welcome; ad hominem is not. Prescribers own their clinical decisions. The community sharpens reasoning. It does not prescribe by committee.

Twelve peptides removed from FDA Category 2. PCAC public meeting July 23–24, 2026. State boards continue to fill in around the federal floor. This is the first edition of PPA's Monthly Regulatory Currency Tracker. Every month, this digest reports what the FDA, DEA, state pharmacy boards, and major clinical bodies are saying about peptide therapy, with primary sources cited for every item. Educational only. Not legal or medical advice. The April 2026 drop is the largest single regulatory event since the September 2024 Category 2 nominator withdrawals. Review it before your next prescription. Verify with your compounding pharmacy. Document the regulatory status in the chart note. —— What's in this edition • Q1 2026 catch-up. January through March 2026 in three pages, for prescribers joining mid-year. • Section 1. FDA 503A bulks list. Twelve peptides removed from Category 2 on April 15, 2026; PCAC public meeting July 23–24, 2026. • Section 2. FDA enforcement. Thirty warning letters to telehealth GLP-1 marketers (March 3); Gram Peptides Research Use Only warning letter (March 31); 503A and 503B exemption reminder (April 1). • Section 3. DEA scheduling and telemedicine. No new federal peptide scheduling in April. Controlled-substance telemedicine flexibility extended through December 31, 2026. • Section 4. State pharmacy boards. California, Texas, Florida, New York, Arizona, plus the next five top states. California's June 2025 Essentially a Copy rule remains the active enforcement vector. • Section 5. Clinical guidance. A4M Peptide Therapy Certification curriculum continues. AACE, AAPS, and ISPRM positions tracked. • Section 6. Telehealth. Federal posture, state posture, what's coming. • Section 7. Notable research. Retatrutide TRIUMPH-4 (December 2025). NEJM SURMOUNT-5 tirzepatide vs. semaglutide head-to-head (2025). • Per-peptide regulatory status table. All 28 peptides covered in the PPA curriculum, in one snapshot. • Upcoming dockets and dates to watch.